Kate Bingham

Kate is Managing Partner at SV Health Investors and serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. Her investments include small-molecule, biotherapeutic and gene therapy drug discovery and development projects as well as drug discovery platforms in a broad range of clinical areas. Kate’s past investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer. In addition to Sitryx, current investments including Artios, Autifony, Bicycle Therapeutics, Enara Bio, Karus Therapeutics, Mestag Therapeutics, Pulmocide, VHSquared and Zarodex. Kate won the 2017 Lifetime Achievement Award, presented by BioIndustry Association UK, and In 2021 was awarded a DBE in the Queen’s Birthday Honours for her services as Chair of the UK Vaccine Taskforce, where she led a team of world-class experts with the shared purposed of finding and manufacturing COVID-19 vaccines. Outside of SV, Kate serves on the Board of the Francis Crick Institute and ARIA. Prior to joining SV, Kate worked in business development for Vertex Pharmaceuticals and at Monitor Company, a strategy consulting firm. Kate has a first-class degree in biochemistry from Oxford University and graduated from Harvard Business School with an MBA (Baker Scholar).